Domino's® Best Deal Ever Offer Has Returned!

Rhea-AI Summary

Alvotech (NASDAQ: ALVO) and Advanz Pharma have entered into a supply and commercialization agreement for AVT10, Alvotech's biosimilar candidate to Cimzia® (certolizumab pegol). The partnership targets the European market, with AVT10 being the only Cimzia® biosimilar under global development.

Cimzia®, a TNF-alpha inhibitor for inflammatory diseases, generated worldwide sales of US$2.3 billion in 2024. The companies plan to launch their first biosimilars in Europe in Q4 2025. This agreement adds to their existing partnership covering biosimilar candidates for more than ten reference biologics.

Positive

• Alvotech's AVT10 is the only Cimzia® biosimilar under development globally
• Partnership expands access to high-value biologics market with Cimzia® 2024 sales of US$2.3 billion
• Agreement strengthens existing partnership covering over 10 biosimilar candidates
• First biosimilar launches expected in Q4 2025

Negative

• Regulatory approvals still pending for biosimilar candidates
• Market entry timeline suggests delayed revenue generation until Q4 2025

Insights

Pharmaceutical Industry Analyst

Alvotech's partnership with Advanz Pharma for Cimzia biosimilar targets $2.3B market with uniquely positioned product for European expansion.

This partnership marks a strategic win for Alvotech in the competitive biosimilar landscape. The company is developing the only global biosimilar candidate for Cimzia® (certolizumab pegol), a TNF-alpha inhibitor with $2.3 billion in worldwide sales last year. This exclusive position gives Alvotech a significant competitive advantage in this particular segment.

What makes this deal particularly valuable is Cimzia's established niche within rheumatic disease treatments, especially for women of childbearing age - a demographic consideration that has helped the reference product secure substantial market share. The agreement expands Alvotech's existing partnership with Advanz Pharma beyond their previously announced collaborations for over ten other biosimilar candidates.

For Alvotech, this represents an expansion of their commercial footprint in Europe, with the first products from this partnership expected to launch in Q4 2025. The timing is strategically aligned with the company's development pipeline and regulatory pathways. For investors, this agreement signals continued execution of Alvotech's business strategy to establish a diverse portfolio of high-value biosimilars and secure strong commercialization partners in key markets.

This deal reinforces Alvotech's position as a significant player in the global biosimilar market, with particular strength in developing complex biosimilar candidates. The expanded partnership with Advanz Pharma provides additional validation of Alvotech's development capabilities and increases the potential revenue streams from their biosimilar portfolio.

Customers can order any pizza with any toppings for $9.99 each

ANN ARBOR, Mich., Aug. 25, 2025 /PRNewswire/ -- Domino's Pizza Inc. (Nasdaq: DPZ) is turning up the heat as summer winds down with the return of its "Best Deal Ever" promotion. For a limited time, starting on Aug. 25, customers can devour any pizza with any toppings for $9.99 each.

For a limited time, starting on Aug. 25, customers can devour any pizza with any toppings for $9.99 each.

"Summer may be wrapping up, but the fun doesn't have to," said Kate Trumbull, Domino's executive vice president – chief marketing officer. "We're bringing back our hottest deal yet so customers can enjoy all sorts of delicious pizza combinations at a great value. Whether you're preparing to send the kids back to school, hosting a Labor Day party or getting ready for football season, Domino's has your meals covered with our 'Best Deal Ever.'"

Domino's $9.99 deal includes Hand Tossed, Handmade Pan, New York Style, Gluten Free and Crunchy Thin Crust, as well as an assortment of sauces and toppings. Customers can upgrade to Parmesan Stuffed Crust for an additional charge.

To order or find the nearest store, visit www.dominos.com or use Domino's mobile app.

About Domino's Pizza^®
Founded in 1960, Domino's Pizza is the largest pizza company in the world, with a significant business in both delivery and carryout. It ranks among the world's top public restaurant brands with a global enterprise of more than 21,500 stores in over 90 markets. Domino's had global retail sales of over $19.4 billion in the trailing four quarters ended June 15, 2025. Its system is comprised of independent franchise owners who accounted for 99% of Domino's stores as of the end of the second quarter of 2025. In the U.S., Domino's generated more than 85% of U.S. retail sales in 2024 via digital channels and has developed many innovative ordering platforms.

Order – dominos.com
Company Info – biz.dominos.com
Media Assets – media.dominos.com

 

 

FAQ

What is the new partnership between Alvotech and Advanz Pharma for?

The partnership is for AVT10, Alvotech's biosimilar candidate to Cimzia® (certolizumab pegol), targeting the European market for inflammatory diseases treatment.

How much were Cimzia® worldwide sales in 2024?

Cimzia® generated worldwide sales of US$2.3 billion in 2024.

When will Alvotech and Advanz Pharma launch their first biosimilars in Europe?

The companies expect to launch their first biosimilars in Europe in Q4 2025.

How many biosimilar candidates are included in the total partnership between Alvotech and Advanz Pharma?

The companies have partnership agreements for biosimilar candidates to more than ten reference biologics.

What makes Alvotech's AVT10 unique in the market?

AVT10 is currently the only biosimilar candidate referencing Cimzia® that is under development globally.